Karyopharm Therapeutics
KPTI
91 hedge funds and large institutions have $49.2M invested in Karyopharm Therapeutics in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 30 reducing their positions, and 31 closing their positions.
1,266% more call options, than puts
Call options by funds: $929K | Put options by funds: $68K
0.44% less ownership
Funds ownership: 3.61% → 3.18% (-0.44%)
16% less capital invested
Capital invested by funds: $58.6M → $49.2M (-$9.41M)
20% less funds holding
Funds holding: 114 → 91 (-23)
33% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 30
71% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$656K |
| 2 |
EP
Eversept Partners
New York
|
+$465K |
| 3 |
Renaissance Technologies
New York
|
+$402K |
| 4 |
D.E. Shaw & Co
New York
|
+$168K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.24M |
| 2 |
Jane Street
New York
|
-$1.11M |
| 3 |
Goldman Sachs
New York
|
-$790K |
| 4 |
Millennium Management
New York
|
-$694K |
| 5 |
Barclays
London,
United Kingdom
|
-$644K |
KPTI Hedge Fund Activity: Q3 2024 in Review
91 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2024, worth a combined $49.2M — down 16% from $58.6M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of KPTI and 9 opened new positions — a net loss of 22 holders — while 30 trimmed existing stakes and 20 added.
The largest buyer was GSA Capital Partners, adding an estimated $656K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.24M sold.
- 91 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2024, down from 114 in Q2 2024.
- Funds reported $49.2M of Karyopharm Therapeutics stock for Q3 2024, down 16% quarter-over-quarter.
- 9 funds opened new Karyopharm Therapeutics positions in Q3 2024 and 31 closed out, a net change of -22 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2024 was GSA Capital Partners, an estimated $656K added.
- The largest Karyopharm Therapeutics seller in Q3 2024 was Opaleye Management, an estimated $1.24M sold.
Based on aggregated 13F filings for Q3 2024.